ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0505

Longitudinal Trajectories of Central Pain Sensitization in People with or at Risk of Knee Osteoarthritis
Abstract Number: 0360

Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Abstract Number: 1869

Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
Abstract Number: 0554

Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset
Abstract Number: 0782

Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
Abstract Number: 1027

Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis
Abstract Number: 0693

Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
Abstract Number: 0165

Low Paraoxonase-1 Enzyme Activity in Patients with Idiopathic Inflammatory Myopathies Associates with Cancer Diagnosis
Abstract Number: 0976

Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Abstract Number: 1318

Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure
Abstract Number: 0060

Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
Abstract Number: 0270

Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
Abstract Number: 2010

Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
Abstract Number: 1393

Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study
Abstract Number: 1569

Lung Involvement in VEXAS Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].